Orgenesis Inc
Change company Symbol lookup
Select an option...
ORGS Orgenesis Inc
LYFT Lyft Inc
AROC Archrock Inc
PACK Ranpak Holdings Corp
NVEE NV5 Global Inc
YARIY Yara International ASA
HYB New America High Income Fund
ACV Virtus Diversified Income & Convertible Fund
XLO Xilio Therapeutics Inc
ORN Orion Group Holdings Inc

Health Care : Biotechnology | Small Cap Blend
Company profile

Orgenesis Inc. is a global biotech company that is operating to unlock the potential of cell and gene therapies (CGTs). The Company is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). It has developed a Point of Care Platform (POCare Platform) comprised of three enabling components, which includes a pipeline of POCare advanced therapies that are designed to be processed and produced, automated closed POCare technology systems, and a worldwide network of POCare research institutes and hospitals (POCare Network). Its products in clinical use include KYSLECEL, Tissue Genesis Icellator for Cell Assisted Lipotransfer, Cartil-S Autologous products for the treatment of osteoarthritis, and Chondroseal Autologous products for the treatment of cartilage defects.

Closing Price
Day's Change
0.13 (5.44%)
B/A Size
Day's High
Day's Low

10-day average volume:

Corporate America's debt sinks to lowest prices since 2008. What comes next hinges on inflation

12:19 pm ET May 11, 2022 (MarketWatch)

By Joy Wiltermuth

Rates volatility has high-grade corporate bonds down almost 14%, on a total return basis

Stocks and crypto aren't the only things getting walloped.

Billions worth of bonds from Fortune 500 companies deemed nearly bulletproof from default also have been tagged in a yard sale for financial assets, as the Federal Reserve works to raise rates and cool inflation at the highest in four decades.

The dollar price of the U.S. investment grade corporate bond index recently fell to $93.5 (see chart), the lowest level since the global financial crisis, according to BofA Global data.

Prices on a host of highly rated corporate bonds in the index have tumbled even lower, during one of the worst stretches in history for total returns.

U.S. investment-grade corporate bonds were pegged at a minus-13.9% total return this year through Monday, compared with negative 9.3% for high-yield bonds, a slide that made it one of the worst performing sectors in fixed-income, according to Mizuho Securities.

"There are several high-quality bonds in the tech space, where the long bonds maturing in 30-years, are trading at 70 to 60 cents on the dollar," Arvind Narayanan, co-head of investment-grade credit at The Vanguard Group, said by phone.

"These are names that are high AA rated, almost AAA, credits," he said, noting the rare discounts on such bonds as global central banks pull pandemic support from markets.

"Companies and their debt have to stand on their own," Narayanan said. "This is a great opportunity for active investors to really generate value for clients."

Tech-wreck, in debt

The past two decades have been known for declining interest rates, translating to years in which investors flocked to the deep well of the U.S. investment-grade corporate bond market for yield.

High demand meant that much of the debt in the investment-graded corporate bond index typically traded at a premium to "par," or above the $100 price many bonds fetch at issuance.

"Only on 15% of days since 2020 the average index price dropped below par," strategists at BofA Global wrote, in a weekly client note. "Currently almost a third (32%) of index notional trades below $90 and 9% -- below $80. Not surprisingly 92% of bonds with prices below $80 are 10yr and longer."

A backdrop of climbing interest rate has led to slashed stock prices for many of the biggest U.S. technology companies, including Apple Inc., (AAPL) Netflix Inc. (NFLX) (AMZN) and Google (GOOGL) parent Alphabet.

It also has spurred a sea of red for corporate bonds this year, particularly for debt maturing in a decade and beyond, according to Bondcliq data. For example, Apple's AA+ rated 2.7% coupon bonds maturing August 2051 were trading at roughly $76 prices on Wednesday.

Interest rate mess

When pricing in the biggest part of the $10 trillion U.S. corporate bond market tumbled in the past it often could be attributed to concerns about "credit issues," such as rising company defaults.

Bankruptcies clearly were a concern when banks were collapsing in 2008, but also initially in 2020 when much of the world adopted lockdowns to slow the spread of COVID 19. Many companies, however, used cheap debt in the past two years to bolster their balance sheets and push out financing needs further down the road.

"It's an unusual situation," said Nick Elfner, co-head of research at Breckinridge Capital Advisors, who said much of the move lower in corporate bond prices over the past six months was rates-driven.

Bonds are priced at a spread, or premium, above risk-free rates. The 10-year Treasury rate was near 2.95% on Wednesday, up from the year's low of about 1.63% on Jan. 3, 2022, according to Dow Jones Market Data. When bond yields move up, prices move down.

"In '09, it was based on credit risks, downgrades and solvency risk in the banking sector," Elfner said, by phone. "Right now, you are sort of seeing the opposite, with upgrades outpacing downgrades, companies having plenty of liquidity, and interest coverage is high."

But he also called the sharp jump in interest rates a "double-edged sword," dealing not only painful losses to bond investors over the shorter-run, but the chance at higher returns later as yields punch higher.

The yield in the ICE BofA US Corporate Index was pegged at 4.4% to start the week, edging closer to the 4.7% peak at the onset of the pandemic in 2020.

As bonds have sold off, some of the froth also has come out of other, more speculative parts of markets, with bitcoin down 36% on the year through Wednesday and the tech-heavy Nasdaq Composite Index off 21%, according to FactSet.

The big question going forward will be if the Fed can tame inflation without sparking a recession, which would reawaken credit concerns for many corporate debt investors.

Against the uncertain backdrop, Vanguard's Narayanan said investors have remained disciplined about how they have been deploying capital. Although, he also said it might mean prices for the yard sale still have further to drop.

-Joy Wiltermuth


(END) Dow Jones Newswires

May 11, 2022 12:19 ET (16:19 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.